266 related articles for article (PubMed ID: 17351625)
1. Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease.
Lee JP; Jeyakumar M; Gonzalez R; Takahashi H; Lee PJ; Baek RC; Clark D; Rose H; Fu G; Clarke J; McKercher S; Meerloo J; Muller FJ; Park KI; Butters TD; Dwek RA; Schwartz P; Tong G; Wenger D; Lipton SA; Seyfried TN; Platt FM; Snyder EY
Nat Med; 2007 Apr; 13(4):439-47. PubMed ID: 17351625
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of stem cells and substrate reduction in juvenile Sandhoff mice.
Arthur JR; Lee JP; Snyder EY; Seyfried TN
Neurochem Res; 2012 Jun; 37(6):1335-43. PubMed ID: 22367451
[TBL] [Abstract][Full Text] [Related]
3. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.
Jeyakumar M; Norflus F; Tifft CJ; Cortina-Borja M; Butters TD; Proia RL; Perry VH; Dwek RA; Platt FM
Blood; 2001 Jan; 97(1):327-9. PubMed ID: 11133779
[TBL] [Abstract][Full Text] [Related]
4. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.
Jeyakumar M; Butters TD; Cortina-Borja M; Hunnam V; Proia RL; Perry VH; Dwek RA; Platt FM
Proc Natl Acad Sci U S A; 1999 May; 96(11):6388-93. PubMed ID: 10339597
[TBL] [Abstract][Full Text] [Related]
5. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation.
Wada R; Tifft CJ; Proia RL
Proc Natl Acad Sci U S A; 2000 Sep; 97(20):10954-9. PubMed ID: 11005868
[TBL] [Abstract][Full Text] [Related]
6. Neural stem cell transplantation benefits a monogenic neurometabolic disorder during the symptomatic phase of disease.
Jeyakumar M; Lee JP; Sibson NR; Lowe JP; Stuckey DJ; Tester K; Fu G; Newlin R; Smith DA; Snyder EY; Platt FM
Stem Cells; 2009 Sep; 27(9):2362-70. PubMed ID: 19591217
[TBL] [Abstract][Full Text] [Related]
7. Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
Denny CA; Heinecke KA; Kim YP; Baek RC; Loh KS; Butters TD; Bronson RT; Platt FM; Seyfried TN
J Neurochem; 2010 Jun; 113(6):1525-35. PubMed ID: 20374428
[TBL] [Abstract][Full Text] [Related]
8. Adeno-associated virus-mediated expression of β-hexosaminidase prevents neuronal loss in the Sandhoff mouse brain.
Sargeant TJ; Wang S; Bradley J; Smith NJ; Raha AA; McNair R; Ziegler RJ; Cheng SH; Cox TM; Cachón-González MB
Hum Mol Genet; 2011 Nov; 20(22):4371-80. PubMed ID: 21852247
[TBL] [Abstract][Full Text] [Related]
9. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
Andersson U; Smith D; Jeyakumar M; Butters TD; Borja MC; Dwek RA; Platt FM
Neurobiol Dis; 2004 Aug; 16(3):506-15. PubMed ID: 15262262
[TBL] [Abstract][Full Text] [Related]
10. Deletion of tumor necrosis factor-α ameliorates neurodegeneration in Sandhoff disease mice.
Abo-Ouf H; Hooper AW; White EJ; Janse van Rensburg HJ; Trigatti BL; Igdoura SA
Hum Mol Genet; 2013 Oct; 22(19):3960-75. PubMed ID: 23727835
[TBL] [Abstract][Full Text] [Related]
11. Metabolic correction in microglia derived from Sandhoff disease model mice.
Tsuji D; Kuroki A; Ishibashi Y; Itakura T; Itoh K
J Neurochem; 2005 Sep; 94(6):1631-8. PubMed ID: 16092933
[TBL] [Abstract][Full Text] [Related]
12. Reversion of the biochemical defects in murine embryonic Sandhoff neurons using a bicistronic lentiviral vector encoding hexosaminidase alpha and beta.
Arfi A; Zisling R; Richard E; Batista L; Poenaru L; Futerman AH; Caillaud C
J Neurochem; 2006 Mar; 96(6):1572-9. PubMed ID: 16441513
[TBL] [Abstract][Full Text] [Related]
13. The beta-hexosaminidase deficiency disorders: development of a clinical paradigm in the mouse.
Tifft CJ; Proia RL
Ann Med; 1997 Dec; 29(6):557-61. PubMed ID: 9562524
[TBL] [Abstract][Full Text] [Related]
14. N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
Baek RC; Kasperzyk JL; Platt FM; Seyfried TN
Neurochem Int; 2008 May; 52(6):1125-33. PubMed ID: 18207611
[TBL] [Abstract][Full Text] [Related]
15. Biology and potential strategies for the treatment of GM2 gangliosidoses.
Chavany C; Jendoubi M
Mol Med Today; 1998 Apr; 4(4):158-65. PubMed ID: 9572057
[TBL] [Abstract][Full Text] [Related]
16. Plasmid-based gene transfer ameliorates visceral storage in a mouse model of Sandhoff disease.
Yamaguchi A; Katsuyama K; Suzuki K; Kosaka K; Aoki I; Yamanaka S
J Mol Med (Berl); 2003 Mar; 81(3):185-93. PubMed ID: 12682727
[TBL] [Abstract][Full Text] [Related]
17. Characterization of inducible models of Tay-Sachs and related disease.
Sargeant TJ; Drage DJ; Wang S; Apostolakis AA; Cox TM; Cachón-González MB
PLoS Genet; 2012 Sep; 8(9):e1002943. PubMed ID: 23028353
[TBL] [Abstract][Full Text] [Related]
18. Embryonic stem cell-derived neural stem cells fuse with microglia and mature neurons.
Cusulin C; Monni E; Ahlenius H; Wood J; Brune JC; Lindvall O; Kokaia Z
Stem Cells; 2012 Dec; 30(12):2657-71. PubMed ID: 22961761
[TBL] [Abstract][Full Text] [Related]
19. Systemic Gene Transfer of a Hexosaminidase Variant Using an scAAV9.47 Vector Corrects GM2 Gangliosidosis in Sandhoff Mice.
Osmon KJ; Woodley E; Thompson P; Ong K; Karumuthil-Melethil S; Keimel JG; Mark BL; Mahuran D; Gray SJ; Walia JS
Hum Gene Ther; 2016 Jul; 27(7):497-508. PubMed ID: 27199088
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice.
Norflus F; Tifft CJ; McDonald MP; Goldstein G; Crawley JN; Hoffmann A; Sandhoff K; Suzuki K; Proia RL
J Clin Invest; 1998 May; 101(9):1881-8. PubMed ID: 9576752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
